Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334-9. doi: 10.1016/j.jtho.2019.09.009. [Epub ahead of print]

PMID:
31605792
2.

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

Shumilov E, Flach J, Pabst T, Fiedler M, Angelillo-Scherrer A, Trümper L, Joncourt R, Kohlmann A, Bacher U.

Crit Rev Oncol Hematol. 2018 Jun;126:64-79. doi: 10.1016/j.critrevonc.2018.03.020. Epub 2018 Mar 29. Review.

PMID:
29759569
3.

Current status and trends in the diagnostics of AML and MDS.

Shumilov E, Flach J, Kohlmann A, Banz Y, Bonadies N, Fiedler M, Pabst T, Bacher U.

Blood Rev. 2018 Nov;32(6):508-519. doi: 10.1016/j.blre.2018.04.008. Epub 2018 Apr 27. Review.

PMID:
29728319
4.

High rate of persistent iatrogenic atrial septal defect after single transseptal puncture for cryoballoon pulmonary vein isolation.

Linhart M, Werner JT, Stöckigt F, Kohlmann AT, Lodde PC, Linneborn LPT, Beiert T, Hammerstingl C, Borràs R, Nickenig G, Andrié RP, Schrickel JW.

J Interv Card Electrophysiol. 2018 Jul;52(2):141-148. doi: 10.1007/s10840-018-0352-0. Epub 2018 Mar 24.

PMID:
29574595
5.

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA.

Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628.

6.

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.

Sherwood JL, Brown H, Rettino A, Schreieck A, Clark G, Claes B, Agrawal B, Chaston R, Kong BSG, Choppa P, Nygren AOH, Deras IL, Kohlmann A.

ESMO Open. 2017 Sep 28;2(4):e000235. doi: 10.1136/esmoopen-2017-000235. eCollection 2017. Erratum in: ESMO Open. 2018 Jan 3;3(1):e000235corr1.

7.

A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories.

Ellison G, Wallace A, Kohlmann A, Patton S.

Br J Cancer. 2017 Aug 22;117(5):710-716. doi: 10.1038/bjc.2017.223. Epub 2017 Jul 27.

8.

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Maria Hernández-Sánchez J, Quijada-Álamo M, María Sánchez-Pina J, Sala-Valdés M, Araujo-Silva F, Kohlmann A, Luis Fuster J, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM.

Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30.

9.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.

10.

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

de Bruin EC, Whiteley JL, Corcoran C, Kirk PM, Fox JC, Armisen J, Lindemann JPO, Schiavon G, Ambrose HJ, Kohlmann A.

PLoS One. 2017 May 4;12(5):e0175779. doi: 10.1371/journal.pone.0175779. eCollection 2017.

11.

Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.

Quijada-Álamo M, Hernández-Sánchez M, Robledo C, Hernández-Sánchez JM, Benito R, Montaño A, Rodríguez-Vicente AE, Quwaider D, Martín AÁ, García-Álvarez M, Vidal-Manceñido MJ, Ferrer-Garrido G, Delgado-Beltrán MP, Galende J, Rodríguez JN, Martín-Núñez G, Alonso JM, García de Coca A, Queizán JA, Sierra M, Aguilar C, Kohlmann A, Hernández JÁ, González M, Hernández-Rivas JM.

J Hematol Oncol. 2017 Apr 11;10(1):83. doi: 10.1186/s13045-017-0450-y.

12.

A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.

Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M, Valiente A, Robledo C, Benito R, Díez-Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM.

Leuk Res. 2017 May;56:82-87. doi: 10.1016/j.leukres.2017.01.031. Epub 2017 Feb 4.

PMID:
28222336
13.

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.

Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L, Sánchez-Del-Real J, Alonso JM, Cuello R, Megido M, Rodríguez JN, Martín-Núñez G, Aguilar C, Vargas M, Martín AA, García JL, Kohlmann A, Del Cañizo MC, Hernández-Rivas JM.

PLoS One. 2016 Oct 14;11(10):e0164370. doi: 10.1371/journal.pone.0164370. eCollection 2016.

14.

Laserballoon and Cryoballoon Pulmonary Vein Isolation in Persistent and Longstanding Persistent Atrial Fibrillation.

Stöckigt F, Kohlmann AT, Linhart M, Nickenig G, Andrié RP, Beiert T, Schrickel JW.

Pacing Clin Electrophysiol. 2016 Oct;39(10):1099-1107. doi: 10.1111/pace.12929. Epub 2016 Aug 30.

PMID:
27484618
15.

The role of the RAS pathway in iAMP21-ALL.

Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ.

Leukemia. 2016 Sep;30(9):1824-31. doi: 10.1038/leu.2016.80. Epub 2016 Apr 22.

16.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, Cai L, Dwight TA, Xu Y, Xu R, Dodd R, Toms A, Parillon L, Lu X, Anjum R, Zhang S, Wang F, Keats J, Wardwell SD, Ning Y, Xu Q, Moran LE, Mohemmad QK, Jang HG, Clackson T, Narasimhan NI, Rivera VM, Zhu X, Dalgarno D, Shakespeare WC.

J Med Chem. 2016 May 26;59(10):4948-64. doi: 10.1021/acs.jmedchem.6b00306. Epub 2016 May 12.

PMID:
27144831
17.

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Salmoiraghi S, Montalvo ML, Ubiali G, Tosi M, Peruta B, Zanghi P, Oldani E, Boschini C, Kohlmann A, Bungaro S, Intermesoli T, Terruzzi E, Angelucci E, Cavattoni I, Ciceri F, Bassan R, Rambaldi A, Spinelli O.

Haematologica. 2016 Jun;101(6):e245-8. doi: 10.3324/haematol.2015.137059. Epub 2016 Mar 18. No abstract available.

18.

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).

Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A.

PLoS One. 2016 Feb 26;11(2):e0150197. doi: 10.1371/journal.pone.0150197. eCollection 2016.

19.

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

Soverini S, De Benedittis C, Papayannidis C, Polakova KM, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G.

Leukemia. 2016 Jul;30(7):1615-9. doi: 10.1038/leu.2016.17. Epub 2016 Feb 12. No abstract available.

PMID:
26867670
20.

Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery.

Zech SG, Kohlmann A, Zhou T, Li F, Squillace RM, Parillon LE, Greenfield MT, Miller DP, Qi J, Thomas RM, Wang Y, Xu Y, Miret JJ, Shakespeare WC, Zhu X, Dalgarno DC.

J Med Chem. 2016 Jan 28;59(2):671-86. doi: 10.1021/acs.jmedchem.5b01552. Epub 2016 Jan 13.

PMID:
26700752
21.

A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.

Hernández JÁ, Hernández-Sánchez M, Rodríguez-Vicente AE, Grossmann V, Collado R, Heras C, Puiggros A, Martín AÁ, Puig N, Benito R, Robledo C, Delgado J, González T, Queizán JA, Galende J, de la Fuente I, Martín-Núñez G, Alonso JM, Abrisqueta P, Luño E, Marugán I, González-Gascón I, Bosch F, Kohlmann A, González M, Espinet B, Hernández-Rivas JM; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC).

PLoS One. 2015 Dec 2;10(11):e0143073. doi: 10.1371/journal.pone.0143073. eCollection 2015.

22.

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2016 Apr;30(4):973-6. doi: 10.1038/leu.2015.207. Epub 2015 Jul 29. No abstract available.

PMID:
26220041
23.

Mutational profiling in patients with MDS: ready for every-day use in the clinic?

Bacher U, Kohlmann A, Haferlach T.

Best Pract Res Clin Haematol. 2015 Mar;28(1):32-42. doi: 10.1016/j.beha.2014.11.005. Epub 2014 Nov 12. Review.

PMID:
25659728
24.

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.

Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, Sanada M, Grossmann V, Sundaresan J, Shiraishi Y, Miyano S, Thol F, Ganser A, Yang H, Haferlach T, Ogawa S, Koeffler HP.

Nat Commun. 2015 Jan 14;6:6042. doi: 10.1038/ncomms7042.

25.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S.

Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. No abstract available.

26.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S.

J Cancer Res Clin Oncol. 2015 May;141(5):887-99. doi: 10.1007/s00432-014-1845-6. Epub 2014 Nov 4.

PMID:
25367136
27.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-5755. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.

28.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T.

Leukemia. 2014 Dec;28(12):2292-9. doi: 10.1038/leu.2014.272. Epub 2014 Sep 12.

PMID:
25212276
29.

A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next-generation sequencing can be revealed by comparative bioinformatic analyses.

Rose D, Kohlmann A, Nagata Y, Ogawa S, Haferlach C, Kern W, Schnittger S, Haferlach T.

Br J Haematol. 2014 Oct;167(2):278-81. doi: 10.1111/bjh.12971. Epub 2014 Jun 12. No abstract available.

PMID:
24925730
30.

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C.

Blood. 2014 Jul 10;124(2):251-8. doi: 10.1182/blood-2014-02-558833. Epub 2014 May 14.

PMID:
24829203
31.

Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, Müdder K, Klein C, Obländer J, Fey S, Vogler J, Fabarius A, Riedl E, Roehl H, Kohlmann A, Staller M, Haferlach C, Müller N, John T, Platzbecker U, Metzgeroth G, Hofmann WK, Trumpp A, Nowak D.

Cell Stem Cell. 2014 Jun 5;14(6):824-37. doi: 10.1016/j.stem.2014.02.014. Epub 2014 Apr 3.

32.

TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.

Hernández-Sánchez M, Rodríguez AE, Kohlmann A, Benito R, García JL, Risueño A, Fermiñán E, De Las Rivas J, González M, Hernández-Rivas JM.

Biomed Res Int. 2014;2014:814294. doi: 10.1155/2014/814294. Epub 2014 Feb 18.

33.

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.

Mühlbacher V, Zenger M, Schnittger S, Weissmann S, Kunze F, Kohlmann A, Bellos F, Kern W, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2014 Jun;53(6):524-36. doi: 10.1002/gcc.22163. Epub 2014 Mar 11.

PMID:
24619868
34.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

PMID:
24523240
35.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Fasan A, Haferlach C, Kohlmann A, Dicker F, Eder C, Kern W, Haferlach T, Schnittger S.

Haematologica. 2014 Feb;99(2):e20-1. doi: 10.3324/haematol.2013.099754. No abstract available.

36.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.

Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2014 May;53(5):402-10. doi: 10.1002/gcc.22151. Epub 2014 Feb 3.

PMID:
24493299
37.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood Cancer J. 2014 Jan 10;4:e173. doi: 10.1038/bcj.2013.71.

38.

Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.

Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A, Thiede C, Borregaard N, Bullinger L, Winther O, Theilgaard-Mönch K, Porse BT.

Blood. 2014 Feb 6;123(6):894-904. doi: 10.1182/blood-2013-02-485771. Epub 2013 Dec 20.

PMID:
24363398
39.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S.

Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.

40.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.

Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N.

Eur J Haematol. 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21.

PMID:
24164563
41.

Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.

Kohlmann A, Bacher U, Schnittger S, Haferlach T.

Leuk Lymphoma. 2014 Aug;55(8):1725-34. doi: 10.3109/10428194.2013.856427. Epub 2014 Feb 14. Review.

PMID:
24144312
42.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, Kern W, Schnittger S.

Leukemia. 2014 Jan;28(1):108-17. doi: 10.1038/leu.2013.263. Epub 2013 Sep 12.

PMID:
24113472
43.

The role of different genetic subtypes of CEBPA mutated AML.

Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S.

Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23.

PMID:
24056881
44.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

45.

Comprehensive mutational profiling in advanced systemic mastocytosis.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A.

Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19.

PMID:
23958953
46.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, Roller A, Kern W, Haferlach C, Schnittger S, Haferlach T.

Leukemia. 2014 Jan;28(1):129-37. doi: 10.1038/leu.2013.239. Epub 2013 Aug 20.

PMID:
23958918
47.

Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients.

Weissmann S, Roller A, Jeromin S, Hernández M, Abáigar M, Hernández-Rivas JM, Grossmann V, Haferlach C, Kern W, Haferlach T, Schnittger S, Kohlmann A.

Leukemia. 2013 Dec;27(12):2393-6. doi: 10.1038/leu.2013.218. Epub 2013 Jul 17. No abstract available.

PMID:
23860447
48.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G.

Blood. 2013 Aug 29;122(9):1634-48. doi: 10.1182/blood-2013-03-487728. Epub 2013 Jun 21.

PMID:
23794064
49.

Robustness of amplicon deep sequencing underlines its utility in clinical applications.

Grossmann V, Roller A, Klein HU, Weissmann S, Kern W, Haferlach C, Dugas M, Haferlach T, Schnittger S, Kohlmann A.

J Mol Diagn. 2013 Jul;15(4):473-84. doi: 10.1016/j.jmoldx.2013.03.003. Epub 2013 May 14.

PMID:
23680131
50.

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.

Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, Roller A, Eder C, Fasan A, Zenger M, Staller M, Kern W, Kohlmann A, Haferlach T.

Leukemia. 2013 Sep;27(9):1940-3. doi: 10.1038/leu.2013.144. Epub 2013 May 7. No abstract available.

PMID:
23648669

Supplemental Content

Loading ...
Support Center